Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVII - AVI BioPharma (Cancer Vaccine) -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (277)	7/28/2007 4:54:53 PM
From: DELT1970	Respond to of 284

avibiotrust.com "Update on the July 25th News Release from Cook and AVI BioPharma Regarding Cook’s Intent to Commercialize AVI’s Restenosis Drug. We are surprised by the market reaction to the Cook/AVI BioPharma press releases regarding the results of recent animal studies, which together with the Resten-MP trial data recently completed, have formed the basis for Cook to move into a major, 20 site clinical trial later this year. We believe this now publicly announced development is significant for AVI BioPharma shareholders and it is not being properly understood or assessed by the market....(continued in link)